Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2024-04-18 DOI:10.1080/09546634.2024.2342383

Joseph F. Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen

引用次数: 0

Abstract

In the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This...

查看原文本刊更多论文

利桑珠单抗对活动性银屑病关节炎患者不同亚组的疗效：对 KEEPsAKE 1 和 KEEPsAKE 2 随机对照试验 3 期的事后综合分析

在 KEEPsAKE 1 (NCT03675308) 和 KEEPsAKE 2 (NCT03671148) 3 期试验中，利桑珠单抗对活动性银屑病关节炎 (PsA) 患者的疗效优于安慰剂。这...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.

文献相关原料

公司名称	产品信息	采购帮参考价格